WO2014128661A1 - Formulation et suspension à usage oral d'un médicament oncologique - Google Patents

Formulation et suspension à usage oral d'un médicament oncologique Download PDF

Info

Publication number
WO2014128661A1
WO2014128661A1 PCT/IB2014/059161 IB2014059161W WO2014128661A1 WO 2014128661 A1 WO2014128661 A1 WO 2014128661A1 IB 2014059161 W IB2014059161 W IB 2014059161W WO 2014128661 A1 WO2014128661 A1 WO 2014128661A1
Authority
WO
WIPO (PCT)
Prior art keywords
sonidegib
kit
container
oil
suspension
Prior art date
Application number
PCT/IB2014/059161
Other languages
English (en)
Inventor
Celine Decaudin
Vincent ROGUE
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to AU2014220339A priority Critical patent/AU2014220339B2/en
Priority to EP14710642.1A priority patent/EP2958550B1/fr
Priority to ES14710642T priority patent/ES2935528T3/es
Priority to PL14710642.1T priority patent/PL2958550T3/pl
Priority to US14/769,110 priority patent/US9943520B2/en
Priority to JP2015558590A priority patent/JP6310484B2/ja
Publication of WO2014128661A1 publication Critical patent/WO2014128661A1/fr
Priority to IL240629A priority patent/IL240629B/en
Priority to ZA2015/06012A priority patent/ZA201506012B/en
Priority to US15/817,854 priority patent/US10426781B2/en
Priority to IL276838A priority patent/IL276838B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture

Definitions

  • Drugs are formulated as suspensions for different reasons, but the most common one is poor drug solubility. Suspensions may also be used to mask the poor taste resulting from the dissolved drug in solution.
  • a suspension unlike syrup in which the drug is fully dissolved, requires adequate shaking of the container to re-suspend the drug uniformly before dosing. Difficult re-dispersion of the drug from a sediment, or in the worst case, from caking, will result in under- and overdosing. This problem of variable dosing is also encountered when the patient or the caregiver forgets to shake the container before dosing. It is therefore desirable to produce a suspension that is able to maintain its homogeneity on prolonged storage without shaking.
  • Sonidegib is also known by its chemical name 2-methyl-4'-trifluoromethoxy- biphenyl-3-carboxylic acid [6-(cis-2,6-dimethyl-morpholin-4-yl)-pyridin-3-yl]-amide or N- [6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[l, - biphenyl]-3-carboxamide.
  • Sonidegib is a potent, selective, brain penetrating, and orally bioavailable
  • the present invention relates to an oral suspension formulation of sonidegib as well as a pharmaceutical kit for the oral suspension itself. It also relates to processes for preparing such compositions. It further relates to method use of the oral suspension. Sonidegib has been challenging to formulate due to poor water solubility and wettability. The formulation provided herein overcomes these challenges.
  • the pharmaceutical kit comprising a first container and a second container, wherein the first container further comprises in dry form sonidegib, a filler, a glident and a lubricant, and the second container further comprises an oil.
  • a suspension can be prepared by dispersing sonidegib in powder form into predefined volume of reconstitution media (oil) for single use or in a bottle for multi-use. The patient individual dose will be applied by using a dosing syringe. The suspension in the syringe can be directly given into the child's mouth.
  • the present invention relates to pharmaceutical compositions comprising sonidegib, a filler, a glident, and a lubricant.
  • the formulation provided herein overcomes poor solubility and wettability issues.
  • the pharmaceutical compositions are useful for treating a variety of different diseases, including Hedgehog dependent brain tumors, such as medulloblastoma.
  • the structure of sonidegib is shown belo
  • sonidegib refers to this compound in its free base form, or as a pharmaceutical acceptable salt.
  • An example of a pharmaceutically acceptable salt form of sonidegib is a phosphate salt, which can include monophosphate and diphosphate.
  • a pharmaceutical composition comprising sonidegib, or a pharmaceutically acceptable salt thereof, a filler, a glident, a lubricant, and an oil.
  • a pharmaceutical composition comprising sonidegib, microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate, and Miglyol 812.
  • the pharmaceutical composition comprises about 30 weight percent sonidegib, about 68 weight percent microcrystalline cellulose, about 0.5 weight percent colloidal silicon dioxide, and about 0.5 weight percent magnesium stearate, relative to the total weight of the sonidegib, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate, and Miglyol 812.
  • a pharmaceutical kit is comprised of a first container, further comprising a mixture of sonidegib, a filler, a glident, and a lubricant; a second container further comprising an oil; and a dispensing syringe, a dosing syringe, or both.
  • the present invention relates to a pediatric dosage form that is a powder for oral suspension by reconstitution in an oily vehicle.
  • the powder may be
  • the powder may be a composition of compounds, including sonidegib in powder form, plus a filler, a glident, and/or a
  • lubricant used in the lubricant.
  • the use of an oily vehicle allows manufacturing a dosage form suitable for patient dose flexibility and a higher bioavailability than the current capsule form (outcomes of relative PK study in healthy volunteers).
  • a preferred oily vehicle is one based on medium-chain triglycerides (MCTs), which are medium-chain (6 to 12 carbons) fatty acid esters of glycerol.
  • MCTs medium-chain triglycerides
  • An example of a MCT is
  • MIGLYOL made from various distillation fractions of coconut oil.
  • Miglyol 812 for example, is a medium chain fatty acid triglyceride.
  • MIGLYOL 812 is composed of 55% triglycerides of C8 and 45% triglycerides of CIO fatty acids.
  • MIGLYOL neutral oils are clear, slightly yellowish esters of saturated coconut and palm kernel oil-derived caprylic and capric fatty acids. This oil is clear, virtually colorless liquid of neutral odor and taste.
  • MCTs Other rich sources include palm kernel oil and camphor tree drupes.
  • the fatty acids found in MCTs are called medium-chain fatty acids.
  • the names of the medium- chain fatty acids (and the corresponding number of carbons) found in MCTs are caproic acid (C6), caprylic acid (C8), capric acid (CIO) and lauric acid (C12).
  • C6 caproic acid
  • C8 caprylic acid
  • CIO capric acid
  • lauric acid C12
  • MCTs are composed of a glycerol backbone and three fatty acids, hence the name triglyceride; in the case of MCTs, 2 or 3 of the fatty acid chains attached to glycerol are medium chain in length. Approximate ratios of these fatty acids in commercial MCT products derived from coconut oil are 2(C6):55(C8):42(C10): 1(C12).
  • the powder and the oily vehicle may be stored together in a single container.
  • the powder i.e. sonidegib in powder form or a
  • composition of compounds including sonidegib in powder form, plus a filler, a glident, and/or a lubricant
  • a pharmaceutical kit comprising a first container, further comprising a mixture of sonidegib, a filler, a glident, and a lubricant; a second container further comprising an oil; and a dispensing syringe, a dosing syringe, or both.
  • the dispensing syringe or dosing syringe is used to transfer a predetermined amount of the sonidegib mixture from the first container to the second container to form a suspension.
  • the suspension can be prepared by dispersing sonidegib in powder form into a predefined volume of reconstitution media (oil) for single use or in a bottle for multi-use.
  • the patient individual dose will be applied by using the dosing syringe.
  • the suspension in the syringe can be directly given into a child's mouth.
  • the oil is a medium chain triglyceride.
  • the medium chain triglyceride is derived from coconut oil.
  • the medium chain triglyceride is a Miglyol.
  • the Miglyol is selected from the group consisting of Miglyol 808, Miglyol 810, Miglyol 812, Miglyol 818, Miglyol 829, Miglyol 840, Miglyol 8108, and Miglyol 8810.
  • the medium chain triglyceride is Miglyol 812.
  • the filler is selected from the group consisting of lactose, dibasic calcium phosphate, saccharide, microcrystalline cellulose, sucrose, dextrose, starch, manitol, and sorbitol, or a mixture thereof. In another embodiment, the filler is microcrystalline cellulose.
  • the glident is selected from the group consisting of fumed silicon dioxide, sodium aluminosilicate, calcium silicate, powdered cellulose, colloidal silicon dioxide, microcrystalline cellulose, corn starch, sodium benzoate, calcium carbonate, magnesium carbonate, talc, metallic stearates, calcium stearate, magnesium stearate, zinc stearate, magnesium lauryl sulfate, and magnesium oxide, or a mixture thereof.
  • the glident is colloidal silicon dioxide.
  • the lubricant is selected from the group consisting of magnesium stearate, colloidal silicon dioxide, talc, calcium stearate, stearic acid, PEG, glyceryl monostearate, potassium benzoate, sodium stearyl fumarate, glyceryl behenate, mineral oil, or a mixture thereof.
  • the lubricant is magnesium stearate.
  • the weight ratio of sonidegib to the filler is within the range of 1 : 1.4-2.8
  • the weight ratio of sonidegib to the glident is within the range of 1 :0.007-0.025
  • the weight ratio of sonidegib to the lubricant is within the range of 1 :0.021 - 0.043.
  • the weight ratio of sonidegib to the filler is about 1 :2.23, the weight ratio of sonidegib to the glident is about 1 :0.0167, and the weight ratio of sonidegib to the lubricant is about 1 : 0.03.
  • the weight percentages of the sonidegib, the filler, the glident, and the lubricant are within the range of 25-35%, 55-75%, 0.3-0.7%, and 0.5-1.5%, respectively, relative to the total weight of sonidegib, the filler, the glident, and the lubricant.
  • the weight percentages of the sonidegib, the filler, the glident, and the lubricant are approximately 30 percent, approximately 68 percent, approximately 0.5 percent, and approximately 1 percent, respectively, relative to the total weight of sonidegib, the filler, the glident, and the lubricant.
  • the ratio of sonidegib to the filler may vary. In one embodiment, the ratio of sonidegib to the filler is about 1 : 1 , by weight. In another embodiment, the ratio of
  • sonidegib to the filler is about 1 : 1.5, by weight. In still another embodiment, the ratio of sonidegib to the filler is about 1 :2, by weight. In still another embodiment, the ratio of sonidegib to the filler is about 1 :2.5 by weight. In yet another embodiment, the ratio of sonidegib to the filler is about 1 :2.8 by weight. In a further embodiment, the ratio of sonidegib to the filler is 1 :3 by weight.
  • the ratio of sonidegib to the glident may also vary. In one embodiment, the ratio of sonidegib to the glident is about 1 : 0.007, by weight. In yet another embodiment, the ratio of sonidegib to the glident is about 1 : 0.008, by weight. In a further embodiment, the ratio of sonidegib to the glident is about 1 : 0.009, by weight. According to another embodiment, the ratio of sonidegib to the glident is about 1 :0.01, by weight. According to yet another embodiment, the ratio of sonidegib to the glident is about 1 :0.0167, by weight. In still another embodiment, the ratio of sonidegib to the glident is about 1.0.02, by weight.
  • the ratio of sonidegib to the glident is about 1 : 0.03, by weight.
  • the ratio of sonidegib to the lubricant may vary. In an embodiment, the ratio of sonidegib to the lubricant is 1 : 0.02, by weight. In another embodiment, the ratio of
  • sonidegib to the lubricant is about 1 :0.03, by weight. In a further embodiment, the ratio of sonidegib to the lubricant is about 1 :0.04, by weight. In still another embodiment, the ratio of sonidegib to the lubricant is about 1 : 0.043, by weight. According to another embodiment, the ratio of sonidegib to the lubricant is about 1 :0.05, by weight.
  • the amount of the oily vehicle may vary depending upon the amount of the powder prescribed per dose such that a suspension is formed.
  • the oil is about 80 rriL.
  • the oil is about 50mL - about lOOmL.
  • the volume of oil may be about 7mL, 10 mL, 15 mL, 20 mL, 25 mL, 30 mL, 35 mL, 40 mL, 45 mL, 50 mL, 55 mL, 60 mL, 65 mL, 70 mL, 75 mL, 80mL, 85 mL, 90 mL, 85 mL, 100 mL or more, or any derivative therein.
  • the oily vehicle may be stored in a container separate from the powder. When it is time for the medication to be
  • the correct amount of powder may be mixed with the correct volume of oily vehicle to create a suspension.
  • the oily vehicle may be stored in a container together with the powder, such that the medication is ready for administration.
  • Tutti Frutti flavor and sucralose are both in the formulation to improve the patient
  • the vehicle, Miglyol 812, has no specific odor or taste.
  • the pharmaceutical composition disclosed herein further comprises a flavor or sweetener.
  • suitable flavoring agents may include those known to the skilled artisan, such as natural, "natural-like" and artificial flavors. These flavors may be chosen, e.g., from synthetic flavor oils, flavoring aromatics, oleo-resins and extracts derived e.g. from plants, leaves, flowers or fruits.
  • Representative flavors may include one or more of spearmint oil, cinnamon oil, peppermint oil, clove oil, bay oil, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds, vanilla, chocolate, coffee, cocoa and citrus oil, lemon, orange, cherry, grape, lime or grapefruit, and fruit essences, e.g. apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple or apricot; mints such as peppermint (including menthol, especially levomenthol), aldehydes and esters, e.g.
  • the pharmaceutical composition comprises sonidegib phosphate, mictrocrystalline cellulose, Tutti Frutti flavor, magnesium stearate, sucralose, colloidal silicon dioxide.
  • the invention can be free of preservatives.
  • the pharmaceutical composition comprises about 1410 mg sonidegib phosphate, about 2149 mg microcrystalline cellulose, about 47 mg Tutti Frutti flavor, about 47 mg magnesium stearate, about 23.5 mg sucralose, about 23.5 mg colloidal silicon dioxide, and 50-100 rriL Miglyol 812, wherein the Miglyol 812 may be combined with the pharmaceutical composition, or stored separately from the pharmaceutical composition and mixed with the pharmaceutical composition prior to administration.
  • the pharmaceutical composition comprises about 5206 mg sonidegib phosphate, about 11627 mg microcrystalline cellulose, about 174 mg Tutti Frutti flavor, about 87 mg magnesium stearate, about 87 mg sucralose, about 174 mg colloidal silicon dioxide, and 50-100 rriL Miglyol 812, wherein the Miglyol 812 may be combined with the pharmaceutical composition, or stored separately from the pharmaceutical composition and mixed with the pharmaceutical composition prior to administration.
  • the pharmaceutical composition comprises sonidegib, microcrystalline cellulose, Tutti Frutti flavor, sucralose, Aerosil 200, magnesium stearate and Miglyol 812.
  • the pharmaceutical composition comprises about 300 mg sonidegib, about 670 mg microcrystalline cellulose, about 10 mg Tutti Frutti flavor, about 5 mg sucralose, about 5 mg Aerosil 200, about 10 mg magnesium stearate; and 50-100 mL Miglyol 812, wherein the Miglyol 812 may be combined and stored together with the pharmaceutical composition, or stored separately from the pharmaceutical composition and mixed with the pharmaceutical composition prior to administration.
  • An example of a pharmaceutical composition of the present invention is sonidegib,
  • microcrystalline cellulose colloidal silicon dioxide, magnesium stearate, and Miglyol 812.
  • carcinomas cancers of the brain, muscle and skin, prostate, glioma, glioblastoma,
  • Enhanced activation of the hedgehog signaling pathway contributes to the pathology and/or symptomology of a number of diseases. Accordingly, molecules that modulate the activity of the hedgehog signaling pathway are useful as therapeutic agents in the treatment of such diseases.
  • a method of treating medulloblastoma in a patient comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition, or a pharmaceutically acceptable salt thereof.
  • the patient is between 0 and 19 years of age.
  • the present invention further provides a method for preventing or treating any of the diseases or disorders described above in a subject in need of such treatment, which method comprises administering to said subject a therapeutically effective amount of the pharmaceutical composition provided herein.
  • the required dosage will vary depending on the mode of administration, the particular condition to be treated and the effect desired.
  • a therapeutically effective amount of the agent is given to a subject using the pharmaceutical compositions provided herein.
  • the term "therapeutically effective" amount is further meant to define an amount resulting in the improvement of any parameters or clinical symptoms.
  • the actual dose may vary with each patient and does not necessarily indicate a total elimination of all disease symptoms.
  • compositions used in the treatment described herein may be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques and by observing results obtained under analogous circumstances.
  • a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound or composition administered; the mode of administration; the bioavailability characteristic of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.
  • an oral suspension for oral administration to children is preferred as it is convenient and the dosage can be accurately controlled.
  • an oral suspension provides high flexibility in controlling the dosage. This facilitates administration to children of different sizes or at different stage of the disease, with varying dosage requirements.
  • an oral suspension allows the use of flavoring and/or palatability agents that can promote patient acceptance and compliance, which can be particularly advantageous when dosing chronically to children.
  • Tutti Frutti flavor and sucralose are both in the formulation to improve the patient
  • the vehicle, Miglyol 812, has no specific odor or taste.
  • a method of treating medulloblastoma in a patient comprising
  • the patient is between 0 and 19 years of age.
  • Treating refers to a method of alleviating or abating a disease and/or its attendant symptoms.
  • the present invention relates to the discovery that signal transduction pathways regulated by hedgehog, patched (Ptc), gli and/or smoothened can be modulated by the pharmaceutical composition contained here.
  • Dissolution of the oral suspension was shown to be immediate and delivery of poorly soluble drug substance with high specific surface area / poor wettability and high dose (up to 600mg).
  • the present invention improved bioavailability and reduce the amount of drug product needed to reach the same effect.
  • Sonidegib has a very high surface area (270 m2/g) and a porous structure that leads to poor water solubility.
  • 1 batch 300 units 1 up to 2000 units i.e. 5206 g up to 34708 g
  • composition Composition Quantity per unit per unit per 34000
  • One unit corresponds to one 125ml amber glass bottle.
  • the drug substance quantity can be adjusted if the content is ⁇ 99.5%. Respective compensation is done by adjusting the Cellulose MK GR content.
  • sonidegib A contained manufacturing process is used as sonidegib is highly potent. Excipients and sonidegib are separately weighed and transferred to container where they are blended.
  • composition is screened and then blended again. Composition is then weighed to be placed in bottles. After composition is placed in bottles, individual adaptors are added. Bottles are closed with a cap. Bottles are labeled and placed in aluminum bag, which is then induction sealed and labeled.
  • the oral suspension provided an AUC than was 36% higher than a conventional capsule and lower variability compared to the other available solid dosage forms.
  • composition of sonidegib 213.7 mg/g powder for oral suspension Composition of sonidegib 213.7 mg/g powder for oral suspension
  • 1.404mg of sonidegib phosphate is equivalent to l.OOOmg of sonidegib free base.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mechanical Engineering (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Cette invention concerne une formulation et une suspension à usage oral d'une composition pharmaceutique comprenant du sonidégib qui est utile pour traiter les maladies liées à l'activité de la voie de signalisation Hedgehog comprenant, par exemple, les cancers du cerveau, du muscle, de la peau, et de la prostate ; les médulloblastomes ; les adénocarcinomes pancréatiques, et les carcinomes du poumon à petites cellules.
PCT/IB2014/059161 2013-02-25 2014-02-21 Formulation et suspension à usage oral d'un médicament oncologique WO2014128661A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2014220339A AU2014220339B2 (en) 2013-02-25 2014-02-21 Oral formulation and suspension of an oncology drug
EP14710642.1A EP2958550B1 (fr) 2013-02-25 2014-02-21 Formulation et suspension à usage oral d'un médicament oncologique
ES14710642T ES2935528T3 (es) 2013-02-25 2014-02-21 Formulación y suspensión oral de un fármaco oncológico
PL14710642.1T PL2958550T3 (pl) 2013-02-25 2014-02-21 Doustna postać użytkowa i zawiesina leku onkologicznego
US14/769,110 US9943520B2 (en) 2013-02-25 2014-02-21 Oral formulation and suspension of an oncology drug
JP2015558590A JP6310484B2 (ja) 2013-02-25 2014-02-21 オンコロジー薬物の経口製剤および懸濁剤
IL240629A IL240629B (en) 2013-02-25 2015-08-17 Oral formulation and suspension of an oncology drug
ZA2015/06012A ZA201506012B (en) 2013-02-25 2015-08-19 Oral formulation and suspension of an oncology drug
US15/817,854 US10426781B2 (en) 2013-02-25 2017-11-20 Oral formulation and suspension of an oncology drug
IL276838A IL276838B (en) 2013-02-25 2020-08-20 Oral formulation and suspension of an oncology drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361768803P 2013-02-25 2013-02-25
US61/768,803 2013-02-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/769,110 A-371-Of-International US9943520B2 (en) 2013-02-25 2014-02-21 Oral formulation and suspension of an oncology drug
US15/817,854 Continuation US10426781B2 (en) 2013-02-25 2017-11-20 Oral formulation and suspension of an oncology drug

Publications (1)

Publication Number Publication Date
WO2014128661A1 true WO2014128661A1 (fr) 2014-08-28

Family

ID=50288200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/059161 WO2014128661A1 (fr) 2013-02-25 2014-02-21 Formulation et suspension à usage oral d'un médicament oncologique

Country Status (11)

Country Link
US (2) US9943520B2 (fr)
EP (1) EP2958550B1 (fr)
JP (1) JP6310484B2 (fr)
AR (1) AR094879A1 (fr)
AU (1) AU2014220339B2 (fr)
ES (1) ES2935528T3 (fr)
IL (2) IL240629B (fr)
PL (1) PL2958550T3 (fr)
TW (2) TWI684462B (fr)
WO (1) WO2014128661A1 (fr)
ZA (1) ZA201506012B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105906616A (zh) * 2015-03-30 2016-08-31 苏州晶云药物科技有限公司 Lde225单磷酸盐的晶型及其制备方法
WO2017163258A1 (fr) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Procédé de préparation de n-[6-(cis-2,6-diméthylmorpholin-4-yl)pyridine-3-yl]-2- méthyl-4'-(trifluorométhoxy) [1,1'-biphényl]-3-carboxamide et de ses polymorphes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033481A1 (fr) * 2008-09-17 2010-03-25 Novartis Ag Sels de n-[6-cis-(2,6-diméthylmorpholin-4-yl)pyridin-3-yl)-2-méthyl-4'-(trifluorométhoxy)-[1,1’-biphényl]-3-carboxamide
US20120122866A1 (en) * 2009-07-21 2012-05-17 Novartis Ag Topical pharmaceutical composition including rel-n-[6-[(2r,6s)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
US8927718B2 (en) * 2009-08-26 2015-01-06 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
JP2012094104A (ja) * 2010-09-29 2012-05-17 Omron Corp 情報処理装置および方法、並びにプログラム

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033481A1 (fr) * 2008-09-17 2010-03-25 Novartis Ag Sels de n-[6-cis-(2,6-diméthylmorpholin-4-yl)pyridin-3-yl)-2-méthyl-4'-(trifluorométhoxy)-[1,1’-biphényl]-3-carboxamide
US20120122866A1 (en) * 2009-07-21 2012-05-17 Novartis Ag Topical pharmaceutical composition including rel-n-[6-[(2r,6s)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4'-(trifluoromethoxy)-[1,1'-biphenyl]-3-carboxamide

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105906616A (zh) * 2015-03-30 2016-08-31 苏州晶云药物科技有限公司 Lde225单磷酸盐的晶型及其制备方法
WO2016155630A1 (fr) * 2015-03-30 2016-10-06 苏州晶云药物科技有限公司 Forme cristalline du monophosphate de n-[6-(forme cis-2,6-diméthylmorpholine-groupe-4)pyridine-groupe-3]-2-méthyl-4'-(trifluorométhoxy)[1,1'-biphényl]-3-formamide et son procédé de préparation
CN105906616B (zh) * 2015-03-30 2018-09-04 苏州晶云药物科技有限公司 Lde225单磷酸盐的晶型及其制备方法
US10266523B2 (en) 2015-03-30 2019-04-23 Crystal Pharmatech Co., Ltd. Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
WO2017163258A1 (fr) * 2016-03-22 2017-09-28 Msn Laboratories Private Limited Procédé de préparation de n-[6-(cis-2,6-diméthylmorpholin-4-yl)pyridine-3-yl]-2- méthyl-4'-(trifluorométhoxy) [1,1'-biphényl]-3-carboxamide et de ses polymorphes

Also Published As

Publication number Publication date
US10426781B2 (en) 2019-10-01
TW201442738A (zh) 2014-11-16
TWI684462B (zh) 2020-02-11
TW202019392A (zh) 2020-06-01
IL240629A0 (en) 2015-10-29
AU2014220339A1 (en) 2015-09-17
EP2958550A1 (fr) 2015-12-30
IL276838A (en) 2020-10-29
JP6310484B2 (ja) 2018-04-11
JP2016510724A (ja) 2016-04-11
PL2958550T3 (pl) 2023-01-16
AU2014220339B2 (en) 2016-12-01
EP2958550B1 (fr) 2022-08-17
IL276838B (en) 2021-05-31
ES2935528T3 (es) 2023-03-07
ZA201506012B (en) 2020-01-29
AR094879A1 (es) 2015-09-02
US9943520B2 (en) 2018-04-17
US20160008369A1 (en) 2016-01-14
TWI696470B (zh) 2020-06-21
US20180071305A1 (en) 2018-03-15
IL240629B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
Watkins Facial sweating after food: a new sign of diabetic autonomic neuropathy
WO2019009927A1 (fr) Compositions de mélange pour administration orale en tant que poudre et/ou suspension à dissolution rapide
BR112012002265B1 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
IL276838A (en) Oral formulation and suspension of an oncology drug
Kini et al. Investigating the suitability of Isomalt and liquid glucose as sugar substitute in the formulation of Salbutamol sulfate hard candy lozenges
JP2007051134A (ja) Ｄ−アロースおよびｄ−プシコースの抗神経因性疼痛効果の利用
JP2009256216A (ja) 溶液状態で安定なアムロジピンベシル酸塩内服用液剤
CN110381921A (zh) 药物制剂
CN106132204A (zh) 西地那非溶液和其制备和使用方法
CA2906060A1 (fr) Procede de traitement de deficience en vitamine b12
JP2007269786A (ja) パンテチン含有経口液剤
BR112019010077A2 (pt) terapias para o tratamento de condições hipocalêmicas e de ineficácia da lidocaína
CN114931552A (zh) 一种口服碱性溶媒组合物及其制备方法与应用
WO2020185214A1 (fr) Comprimés à désintégration orale comprenant du glycopyrrolate et procédés pour augmenter la biodisponibilité
WO2012066401A1 (fr) Compositions pharmaceutiques orales stables de montélukast
RU2684330C1 (ru) Композиции фулвестранта
WO2021019479A2 (fr) Nouvelles formulations d'amisulpride
Njoroge et al. Evaluating Corchorus olitorius plant mucilage in the formulation of oro-dispersible paediatric sildenafil tablets
Nahornyi et al. Development of technology and research of gel with pentoxifylline
Panda et al. Formulation, Development and Evaluation of Sildenafil Citrate Oral Jelly
RU2546300C1 (ru) Композиция, обладающая действием на центральную нервную систему и ее применение
KR20240004683A (ko) 알펠리십 제형
WO2018222163A9 (fr) Utilisation d'une préparation à base d'herbes contenant de l'huile de pépins de courge dans le traitement de la vessie hyperactive et de l'incontinence urinaire des symptômes du système urinaire inférieur
WO2020215238A1 (fr) Préparation de carbonate de calcium d3 soluble dans l'eau
WO2020097211A1 (fr) Compositions topiques comprenant de la pentoxifylline et méthodes de traitement faisant appel à celles-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14710642

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 240629

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 14769110

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015558590

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014710642

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014220339

Country of ref document: AU

Date of ref document: 20140221

Kind code of ref document: A